Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...

Axsome Therapeutics (NASDAQ:AXSM) announced Wednesday a settlement agreement with U.K.-based Hikma Pharmaceuticals ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by ...

Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast ...

Hikma Pharmaceuticals PLC HIK shares dropped 6.18% to £21.54 Wednesday, on what proved to be an all-around positive trading ...

Mercaptopurine oral suspension is indicated for the treatment of patients with acute lymphoblastic leukemia as part of a ...

Shares in Hikma Pharmaceuticals came under pressure in early trading on Wednesday, despite a jump in annual revenues, after ...

Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn ...

Amman, Jordan: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the ...

Hikma's generics business, grew 9 per cent to $1.026 billion, surpassing the $1 billion revenue mark for the first time.

(Alliance News) - Hikma Pharmaceuticals PLC on Wednesday said it planned to increased spending on research and development to support further growth after reporting strong annual results. The ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...